Sobi To Appeal Against EMA Rejection For Emapalumab
Executive Summary
The company says its drug has demonstrated a positive benefit-risk profile in primary HLH in a post-approval real-life setting in the US since Food and Drug Administration approval in 2018.
You may also be interested in...
EMA Recommends Stemline’s Elzonris After Initial Rejection
While the European Medicine Agency now recommends that Elzonris should be approved in the EU, Stemline Therapeutics will have to submit the results of a study based on a registry of patients with blastic plasmacytoid dendritic cell neoplasm.
EMA Dashes Sobi’s EU Gamifant Marketing Hopes
The European Medicine Agency has stood firm on its decision to recommend against pan-EU marketing approval for Gamifant.
Winners And Losers: A Deep-Dive Into The EMA’s PRIME Scheme
Nine of the 70 medicines for unmet medical needs that have to date won a place on the European Medicines Agency’s PRIME scheme are now approved for sale in the EU, and two more approvals are expected soon. Meanwhile, most applications for a "priority medicine" designation are still missing the mark.